Colorado BioScience Association celebrates state’s collaboration in new magazine issue

Wednesday June 5, 2019 0 comments Tags: Denver, CBSA, Jennifer Jones Paton, Emily Roberts

DENVER -- Colorado BioScience Association (CBSA) today launched the new issue of its annual magazine, BioScience Colorado: Collaborative by Nature, at the 2019 BIO International Convention in Philadelphia.CBSA_logoUSE

The 2019-2020 magazine highlights Colorado’s reputation for collaboration, profiles companies focused on engaging patients in the product design and development process, and details the successes of the state-supported Advanced Industries grant program.

“Colorado’s life science ecosystem stands apart because of our commitment to solving business challenges together,” said Jennifer Jones Paton, CBSA CEO.

“Our member companies, academic and research institutions, and partners collaborate to improve the lives of patients here in Colorado and around the world. We titled our new BioScience Colorado magazine Collaborative by Nature because of the close working relationships in our ecosystem.”

BioScience Colorado 2019-2020: Collaborative by Nature provides comprehensive data on the state’s life science industry, with detailed information on topics of interest, including:

Advanced Industry Grants

Since inception, the state-funded Advanced Industries Grant program has awarded 413 grants to life science companies, creating 773 direct jobs, 79 new companies and $551.7 million in follow-on grants and investments.

Financing

Colorado life science companies raised $1 billion in 2018. The magazine breaks down investments by company name and deal type.

Medical Device Approvals

In 2018, 219 medical devices and diagnostics developed by Colorado companies received 510(K) approval from the FDA, and 5 achieved a PMA designation. In-vitro diagnostics, cardiovascular, and orthopedics were the largest categories of medical devices in approved or investigational status.

Pharmaceutical Trials by Therapy Area

Colorado pharmaceutical companies participated in 1,140 clinical trials in 2018. Top drugs and trials by therapy area included oncology, central nervous system and infectious disease.

“The annual magazine provides new insights on the breakthroughs happening here and in-depth information on recent investments, grants, drug and device trials, and product approvals.,” said Emily Roberts, CBSA VP.

“CBSA members and partners use the annual magazine to share our life science success stories with prospective investors, potential partners and out-of-state talent considering a move to Colorado.”

CBSA members will receive a copy of the magazine via mail. Additional copies are available at any CBSA event or by request. An electronic version of the magazine is available on the CBSA website.